Trial Profile
A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pegmolesatide (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 25 Feb 2015 New trial record